SMN1 and non-small cell lung carcinoma: Multiple human tissue analyses have shown that α-smooth muscle actin (SMA)-positive myoCAFs are linked to poor prognosis in many cancer types1 and to immunotherapy resistance in non-small cell lung cancer (NSCLC)7.